Compositions and Methods for Diagnosing and Treating Cancer

Abstract

An isolated antibody that specifically binds to an extracellular domain of human DDR2 and has a therapeutic effect on a solid tumor is described. Also described is a method of treating cancer, the method comprising administering to a patient having a solid tumor an antibody of the present disclosure in a therapeutically effective amount.

1 - 34 . (canceled) 
     
     
         35 . A method of treating cancer, the method comprising:
 administering to a patient with a solid tumor a therapeutically effective amount of a monoclonal antibody that specifically binds human DDR2 within a region comprising amino acids 24 to 241.   
     
     
         36 . The method of  claim 35 , wherein the antibody binds the discoidin/coagulation domain of human DDR2. 
     
     
         37 . The method of  claim 35 , wherein the antibody is a chimeric antibody. 
     
     
         38 . The method of  claim 35 , wherein the antibody is a humanized antibody. 
     
     
         39 . The method of  claim 35 , wherein the antibody is a human antibody. 
     
     
         40 . The method of  claim 35 , wherein the antibody is antibody 9M58. 
     
     
         41 . The method of  claim 35 , wherein the antibody is conjugated to a cytotoxic moiety. 
     
     
         42 . The method of  claim 35 , further comprising administering at least one additional therapeutic agent to the patient. 
     
     
         43 . The method of  claim 35 , wherein the antibody is administered in a pharmaceutical composition. 
     
     
         44 . The method of  claim 35 , wherein the solid tumor is selected from the group consisting of a breast tumor, colorectal tumor, lung tumor, pancreatic tumor, prostate tumor, and a head and neck tumor. 
     
     
         45 . A method of treating cancer, the method comprising:
 administering to a patient with a solid tumor a therapeutically effective amount of a monoclonal antibody that competes for specific binding to human DDR2 with the antibody 9M58 which is produced by the hybridoma deposited with ATCC having deposit number PTA-10415.   
     
     
         46 . The method of  claim 45 , wherein the antibody competes for specific binding within the region comprising amino acids 24 to 241 of human DDR2. 
     
     
         47 . The method of  claim 45 , wherein the antibody competes for specific binding to the discoidin/coagulation domain of human DDR2. 
     
     
         48 . The method of  claim 45 , wherein the antibody is a chimeric antibody. 
     
     
         49 . The method of  claim 45 , wherein the antibody is a humanized antibody. 
     
     
         50 . The method of  claim 45 , wherein the antibody is a human antibody. 
     
     
         51 . The method of  claim 45 , wherein the antibody is conjugated to a cytotoxic moiety. 
     
     
         52 . The method of  claim 45 , further comprising administering at least one additional therapeutic agent to the patient. 
     
     
         53 . The method of  claim 52 , wherein the additional therapeutic agent is a chemotherapeutic agent. 
     
     
         54 . The method of  claim 45 , wherein the antibody is administered in a pharmaceutical composition. 
     
     
         55 . The method of  claim 45 , wherein the solid tumor is selected from the group consisting of a breast tumor, colorectal tumor, lung tumor, pancreatic tumor, prostate tumor, and a head and neck tumor.